Trevi Therapeutics Inc. has announced the appointment of David Hastings as Chief Financial Officer and principal financial officer, effective January 6, 2026. Under the terms of his offer letter, Hastings will receive an annualized base salary of $522,000 and will be eligible for an annual incentive bonus of up to 40% of his base salary. In addition, upon commencing employment, he will be granted an option to purchase 375,000 shares of the company's common stock at the closing price on the date of grant. The stock option will vest 25% after one year, with the remainder vesting in equal monthly installments over the following three years. Hastings will also be eligible for separation benefits under the company's Executive Separation Benefits and Retention Plan.